Despite the associated high probability of fetal risks in pregnant patients, mycophenolate remains one of the most commonly used immunosuppressants for patients receiving a solid organ transplant (SOT). To help combat the risks associated with mycophenolate treatment, the ongoing FDA mycophenolate Risk Evaluation and Mitigation Strategy (MREMS) program was introduced in 2012 with a focus on very specific safe-use behaviors to ensure prevention of prenatal exposures to mycophenolate. Although MREMS was introduced over a decade ago, evidence shows that clinician adoption in practice is suboptimal. Engaging and sustained educational efforts are needed in 2024 to not only raise awareness of the mycophenolate REMS, but also to drive improved implementation of the program in practice. Please join a panel of expert multidisciplinary faculty in a compelling CMEO recorded webcast on how to better evaluate toxicity and pregnancy risks in patients taking mycophenolate, counsel patients of reproductive potential, monitor relevant pregnancies and patient reporting to the Mycophenolate Pregnancy Registry, and implement MREMS in clinical practice.
- Provider:CME Outfitters, LLC
- Activity Link: https://www.cmeoutfitters.com/activity/why-are-we-still-talking-about-the-mycophenolate-rems-in-2024-2/
- Start Date: 2024-10-16 05:00:00
- End Date: 2024-10-16 05:00:00
- Credit Details: IPCE Credits: 1.0 hours
AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Dentistry: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours
Psychology: 1.0 hours - MOC Credit Details: ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Mycophenolate REMS - Amount: 0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Internal Medicine